Eli Lilly's tirzepatide, marketed under the brands Mounjaro for diabetes and Zepbound for weight management, is highly ...

The side effects from popular weight loss medications can be tougher than expected. Findings from a recent study found that ...

Longevity doctors warn GLP-1 drugs may cost patients muscle, not just fat. ShapeScale’s 3D scans reveal the loss—and help ...

Patients with systemic lupus erythematosus (SLE) and type 2 diabetes, with and without lupus nephritis (LN), had a lower risk ...

Pfizer acquired a smaller company for $4.9 billion to improve its prospects in the GLP-1 market. The pharmaceutical giant could carve out a small niche for itself in this growing space. Pfizer's ...

For years, the pancreas has been being taught in biology class as an easy system: insulin lowers blood sugar, and glucagon ...

GLP-1 initiation was common among patients who underwent bariatric surgery, especially sleeve gastrectomy vs Roux-en-Y gastric bypass.

Eli Lilly's GLP-1 Pill Just Beat Out Novo Nordisk's in a Test. Here's 1 Thing Investors Need to Know. The secondary endpoints ...

The FDA will decide on whether to approve the first oral formulation of a GLP-1 (once-daily semaglutide 25 mg) for chronic ...

Excellus BlueCross BlueShield is pushing back against reports that it will no longer cover GLP-1 medications, saying drugs ...

The WHO has added GLP-1 agonists to its Essential Medicines List in 2025. Learn more about the impact of this decision.

"However, in clinical trials, GLP-1 agonists reduce mortality by about 20%, and no single pharmaceutical treatment has ever ...